Pharmacological treatment strategies in acute schizophrenia

被引:8
|
作者
Marder, SR [1 ]
机构
[1] UNIV CALIF LOS ANGELES,SCH MED,DEPT PSYCHIAT & BIOBEHAV SCI,LOS ANGELES,CA 90024
关键词
schizophrenia; antipsychotic; clozapine; risperidone; sertindole; olanzapine; seroquel;
D O I
10.1097/00004850-199605002-00005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
It may be helpful for clinicians to consider the management of schizophrenia as occurring in three different phases: an acute phase which lasts about 4-8 weeks, a resolving phase which lasts about 4-6 months and a stable phase which lasts as long as the patient remains in remission. During the acute phase, patients demonstrate active symptoms of schizophrenia. The goal of treatment during this phase is to reduce the most severe symptoms of the illness, particularly positive symptoms. Nearly all acute episodes should be treated with an antipsychotic medication. Moreover, drug treatment should occur as early in this phase as possible. Certain treatment principles should guide management: an antipsychotic drug and dose should be used that appropriately balances side effects and efficacy. Trial of the selected drug(s) should last at least 4-6 weeks before the medication is changed. Newer antipsychotics have clear advantages over older drugs in terms of side effects and efficacy. Greater use of these agents may improve the outcome in acute schizophrenia.
引用
收藏
页码:29 / 34
页数:6
相关论文
共 50 条
  • [1] PHARMACOLOGICAL STRATEGIES IN THE TREATMENT OF SCHIZOPHRENIA
    RIFKIN, A
    PSYCHIATRIC CLINICS OF NORTH AMERICA, 1993, 16 (02) : 351 - 363
  • [2] Pharmacological treatment of acute agitation in schizophrenia
    Bianchini, O.
    Porcelli, S.
    Aguglia, E.
    De Ronchi, D.
    Serretti, A.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S470 - S471
  • [3] Treatment of cognitive deficits in schizophrenia - Part 2: Pharmacological strategies
    Roesch-Ely, D.
    Pfueller, U.
    Mundt, C.
    Mueller, U.
    Weisbrod, M.
    NERVENARZT, 2010, 81 (05): : 564 - 576
  • [4] New pharmacological treatment strategies targeting GABAergic dysfunction in schizophrenia
    Vinkers, C. H.
    EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2013, 23 : S153 - S154
  • [5] Neurosteroids and pharmacological treatment strategies in schizophrenia, depression, and anxiety disorders
    Marx, CE
    Barbaccia, ML
    Guidotti, A
    Rupprecht, R
    Morrow, AL
    BIOLOGICAL PSYCHIATRY, 2002, 51 (08) : 94S - 94S
  • [6] Update on novel antipsychotics and pharmacological strategies for treatment-resistant schizophrenia
    de Bartolomeis, Andrea
    Ciccarelli, Mariateresa
    Vellucci, Licia
    Fornaro, Michele
    Iasevoli, Felice
    Barone, Annarita
    EXPERT OPINION ON PHARMACOTHERAPY, 2022, 23 (18) : 2035 - 2052
  • [7] Pharmacological treatment of schizophrenia
    Fleishhacker, WW
    EUROPEAN PSYCHIATRY, 2000, 15 : 314S - 314S
  • [8] Pharmacological Treatment of Schizophrenia
    Leucht, S.
    Heres, S.
    Kissling, W.
    Davis, J. M.
    FORTSCHRITTE DER NEUROLOGIE PSYCHIATRIE, 2013, 81 (05) : 284 - 284
  • [9] The Pharmacological Treatment of Schizophrenia
    不详
    PSYCHIATRIC QUARTERLY, 1938, 12 (04) : 796 - 797
  • [10] Pharmacological treatment of schizophrenia
    Gadelha, Ary
    Noto, Cristiano Souza
    Mari, Jair de Jesus
    INTERNATIONAL REVIEW OF PSYCHIATRY, 2012, 24 (05) : 489 - 498